Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
Christine H. Chung(Moffitt Cancer Center), Barbara A. Murphy(Vanderbilt University Medical Center), Jessica L. Baumann(Vanderbilt University), Joseph M. Aulino(Vanderbilt University), Robert J. Sinard(Vanderbilt University Medical Center), Nancy J. Muldowney, Brian B. Burkey(University of Colorado Cancer Center), James L. Netterville(Breast Cancer Research Foundation), Jeremy L. Gilbert(Medical University of South Carolina), Anthony J. Cmelak(Breast Cancer Research Foundation), Hiromitsu Hatakeyama(Yokohama City University Medical Center), Joel S. Parker(University of North Carolina at Chapel Hill), Wendell G. Yarbrough(University of North Carolina at Chapel Hill), Yu Shyr(Vanderbilt University), Robbert J.C. Slebos(University of Iowa)
Cited by 62
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2004|3.2k
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
|Breast Cancer Research|2010|2.1k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k